Patent application number | Description | Published |
20090011075 | Polar Lipid Mixtures, their Preparation and Uses - Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein. | 01-08-2009 |
20090074857 | Glycerophospholipids for the improvement of cognitive functions - Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids. | 03-19-2009 |
20090232916 | FOOD PRODUCTS FOR DIABETICS - Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain/loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof. | 09-17-2009 |
20100069332 | Lipids containing omega-3 and omega-6 fatty acids - A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes. | 03-18-2010 |
20100184734 | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy - Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and/or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions associated with lipid metabolism, such as atherosclerosis, diabetes, metabolic disorders, etc. Compositions, dietary nutrients, food supplements and nutraceuticals comprising the herein described mixtures are also described. | 07-22-2010 |
20110144063 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 06-16-2011 |
20110244071 | EDIBLE FAT COMPOSITION FOR ENHANCING BONE STRENGTH - Disclosed is describes a method of increasing bone strength and/or increasing bone resistance to bending and/or improving bone architecture and/or maintaining bone status in a human, comprising administering to said human a composition comprising a fat source, wherein said fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% (w/w) of total palmitic acid. Said method is particularly intended for subjects at risk of impaired bone strength. Further disclosed is said fat source, as well as food articles and a commercial package comprising the same. | 10-06-2011 |
20110294757 | POLAR LIPID MIXTURES, THEIR PREPARATION AND USES - Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein. | 12-01-2011 |
20120288531 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF FERRIC IRON COMPOUNDS, AND METHODS OF USE THEREOF - The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound. | 11-15-2012 |
20140051663 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 02-20-2014 |
Patent application number | Description | Published |
20090029407 | Systems And Methods For Analyzing And Manipulating Biological Samples - A system for qualifying cells of a cell sample labeled with a magnetic or magnetizable moiety is provided. The system includes a cell sample holder for holding a cell of the cells and a first cell analyzer which includes a magnetic field source for applying a magnetic field to the cell and a sensor for qualifying and/or quantifying an effect of the magnetic field on the cell. | 01-29-2009 |
20090214649 | Scaffolds with oxygen carriers, and their use in tissue regeneration - Provided are fibrin or silk matrices comprising an oxygen carrier, and matrices, which comprise an oxygen carrier and mesenchymal stem cells. Also provided are methods of generating and using same for ex vivo or in vivo tissue regeneration and/or repair such as for treating a non-union bone fracture and a condition requiring spinal fusion. | 08-27-2009 |
20100209400 | TAK1-Mediated Regulation of Osteogenesis - This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects. | 08-19-2010 |
20110217730 | SYSTEMS AND METHODS FOR ANALYZING AND MANIPULATING BIOLOGICAL SAMPLES - A system for qualifying cells of a cell sample labeled with a magnetic or magnetizable moiety is provided. The system includes a cell sample holder for holding a cell of the cells and a first cell analyzer which includes a magnetic field source for applying a magnetic field to the cell and a sensor for qualifying and/or quantifying an effect of the magnetic field on the cell. | 09-08-2011 |
20120078163 | METHOD OF GENERATING CONNECTIVE TISSUE - A method of generating bone or connective tissue in a subject in need thereof, the method comprising: (a) implanting a scaffold in a damaged region of the subject, the scaffold comprising a tissue growth promoting agent; and (b) enhancing uptake of the tissue growth promoting agent into cells located on the scaffold, wherein the enhancing is effected by induced poration of the cells thereby generating bone or connective tissue in the subject. Kits for generating bone or connective tissue are also provided. | 03-29-2012 |
20120082704 | Oxygenated demineralized bone matrix for use in bone growth - An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone. | 04-05-2012 |
Patent application number | Description | Published |
20110319991 | Low Profile Transcatheter Heart Valve - An implantable prosthetic valve, according to one embodiment, comprises a frame, a leaflet structure, and a skirt member. The frame can have a plurality of axial struts interconnected by a plurality of circumferential struts. The leaflet structure comprises a plurality of leaflets (e.g., three leaflets arrange to form a tricuspid valve). The leaflet structure has a scalloped lower edge portion secured to the frame. The skirt member can be disposed between the leaflet structure and the frame. | 12-29-2011 |
20130018458 | PERIVALVULAR SEALING FOR TRANSCATHETER HEART VALVE - The present disclosure is directed to embodiments of catheter-based prosthetic heart valves, and in particular, prosthetic heart valves having sealing devices configured to seal the interface between the prosthetic valve and the surrounding tissue of the native annulus in which the prosthetic valve is implanted. In one embodiment, a prosthetic heart valve includes an annular sealing member that can be placed in a delivery orientation extending axially away from one end of the valve when the valve is in a radially compressed state. When the valve is expanded, the expansion of the frame causes the sealing member to be pulled to an operative orientation covering a portion of the frame. The present disclosure also discloses new mechanisms and techniques for mounting valve leaflets to a frame of a prosthetic heart valve. | 01-17-2013 |
20140209238 | METHODS OF MAKING ENCAPSULATED HEART VALVES - The present disclosure concerns embodiments of implantable prosthetic devices, and in particular, implantable prosthetic valves, and methods for making such devices. In one aspect, a prosthetic device includes encapsulating layers that extend over a fabric layer and secure the fabric layer to another component of the device. In particular embodiments, the prosthetic device comprises a prosthetic heart valve, and can be configured to be implanted in any of the native heart valves. In addition, the prosthetic heart valve can be, for example, a transcatheter heart valve, a surgical heart valve, or a minimally-invasive heart valve. | 07-31-2014 |
20140343671 | PERIVALVULAR SEALING FOR TRANSCATHETER HEART VALVE - The present disclosure is directed to embodiments of catheter-based prosthetic heart valves, and in particular, prosthetic heart valves having sealing devices configured to seal the interface between the prosthetic valve and the surrounding tissue of the native annulus in which the prosthetic valve is implanted. In one embodiment, a prosthetic heart valve includes an annular sealing member that can be placed in a delivery orientation extending axially away from one end of the valve when the valve is in a radially compressed state. When the valve is expanded, the expansion of the frame causes the sealing member to be pulled to an operative orientation covering a portion of the frame. The present disclosure also discloses new mechanisms and techniques for mounting valve leaflets to a frame of a prosthetic heart valve. | 11-20-2014 |